Sanaregen Vision Therapeutics, Inc. is a clinical-stage biopharmaceutical research and development company that is developing one of the first regenerative medicine treatments designed to effectively treat degenerative retinal diseases. With creative trial design, iterative development, and platform technology with multimodal capabilities, we create potential for accelerated approvals and first-to-market positioning.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 1831 12th Ave S,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.sanaregenvision.com
- Keywords
- Regenerative Medicine, Macular Degeneration, Degenerative Retinal Disease, Retinopathies, Stem Cells, Vision Restoration, Geographic Atrophy.
- HQ
- Nashville, Tennessee
Sanaregen™ Vision Therapeutics Questions
Sanaregen™ Vision Therapeutics's website is https://www.sanaregenvision.com
Sanaregen™ Vision Therapeutics's LinkedIn profile is https://www.linkedin.com/company/sanaregenvision
Sanaregen™ Vision Therapeutics has
2 employees.
View email and phone details for 2
employees at Sanaregen™ Vision Therapeutics.
Sanaregen™ Vision Therapeutics's industry is
Biotechnology Research
Sanaregen™ Vision Therapeutics's top competitors are
Aim Immunotech,
Brandaid Group, Inc.,
Myosin Therapeutics Inc.,
Longeveron,
Eliances, Where Entrepreneurs Align,
American Injectables,
Regenerative Outcomes,
Micropure Genomics Inc.,
American Cell Technology,
Sana Holding.
Sanaregen™ Vision Therapeutics's categories are Biotechnology Research
Sanaregen™ Vision Therapeutics's founding year is 2024
